Published in Pharm Res on March 14, 2016
Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in Women | NCT02357602
Application of electrospun fibers for female reproductive health. Drug Deliv Transl Res (2017) 0.84
Long acting systemic HIV pre-exposure prophylaxis: an examination of the field. Drug Deliv Transl Res (2017) 0.82
Carriers for the tunable release of therapeutics: etymological classification and examples. Expert Opin Drug Deliv (2016) 0.75
The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women. Curr HIV/AIDS Rep (2017) 0.75
A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective. Infect Dis Ther (2017) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
Stopping antiretroviral therapy. AIDS (2007) 2.63
Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav (2013) 2.03
The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials (2005) 2.01
Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS (2013) 1.73
Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother (2005) 1.63
Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis. Annu Rev Med (2012) 1.36
Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother (2010) 1.35
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr (2013) 1.31
Modeling of diffusion controlled drug delivery. J Control Release (2011) 1.20
GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr (2014) 1.07
Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob Agents Chemother (2015) 0.99
Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharm (2012) 0.98
An overview of antiretroviral pre-exposure prophylaxis of HIV infection. Am J Reprod Immunol (2014) 0.87
Polycaprolactone thin-film drug delivery systems: Empirical and predictive models for device design. Mater Sci Eng C Mater Biol Appl (2015) 0.84
In Vitro and In Vivo Sustained Zero-Order Delivery of Rapamycin (Sirolimus) From a Biodegradable Intraocular Device. Invest Ophthalmol Vis Sci (2015) 0.83
Editorial Commentary: Unmasking the Bare Bones of HIV Preexposure Prophylaxis. Clin Infect Dis (2015) 0.79